Shingrix reduces cardiovascular disease risk
Analysis based on 29 articles · First reported Aug 26, 2026 · Last updated Aug 29, 2026
The study could boost demand for Zoster vaccine, benefiting its manufacturer, and may influence vaccination policies for older adults. If confirmed, it could reduce healthcare costs and improve public health, but the observational nature limits immediate market impact.
A study led by Maxime Taquet at the University of Oxford, published in Nature Medicine, analyzed health records of over 70,000 US adults aged 60 and older from the TriNetX database. The study leveraged the 2017 switch from the Zoster vaccine to the Zoster vaccine shingles vaccine in the United States as a natural experiment. It found that recipients of Zoster vaccine had a 12% lower risk of cardiovascular events (heart attack, stroke, heart failure) in the first 3.5 years after vaccination, with a 9% longer time without cardiovascular disease over seven years. The protective effect was strongest for ischemic heart disease and heart failure, and was significant in men for ischemic stroke. The benefit waned over time but remained. The mechanism is unclear but may involve reduced inflammation or better shingles prevention. The findings are observational and require confirmation by randomized controlled trials, including an ongoing trial in Denmark. If confirmed, Zoster vaccine could prevent hundreds of thousands of cardiovascular cases and be comparable to antihypertensive medication. The United Kingdom — National Health Service in the United Kingdom offers Zoster vaccine to older adults. Experts including John Tregoning, Betty Raman, Paul Harrison, and Hugo Pedder commented on the study.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard